Last reviewed · How we verify

NCT03366181

SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.

Completed Last updated 20 January 2025
What this trial tests

trial in Heart Failure in 500 participants. Completed in 26 November 2017.

Timeline
1 November 2017
Primary endpoint
20 November 2017
26 November 2017

Quick facts

Lead sponsorUniversity of Campania Luigi Vanvitelli
StatusCompleted
Study typeOBSERVATIONAL
Enrollment500
Start date1 November 2017
Primary completion20 November 2017
Estimated completion26 November 2017
Sites1 location across Italy

Conditions studied

Sponsor

University of Campania Luigi Vanvitelli

Who can join

Adults 18 to 75, any sex, with Heart Failure or ICD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Failing heart negative remodeling alterations might provide electrical heterogeneity and cardiac remodeling, thus potentially contributing to the occurrence of ventricular arrhythmia and subsequent sudden cardiac death (SCD). In this study we have prospectively investigated whether sodium glucose transporte-2 inhibitors (SGLT2i) could modulate serum markers of heart failure (ultra sensitive Troponin , B type Natriuretic Peptide (BNP), C reactive protein (CRP), the heart rate (HR) and serum catecholamines in patients with type 2 diabetes mellitus (T2DM), and be used as predictors for the occurrence of malignant ventricular arrhythmias (VTAs) in patients who had received an Implantable Cardioverter Defibrillator (ICD) for primary prevention. In these T2DM patients with ICD we investigated the functionality of devices, the appropriate and inappropriate shocks, and the hospitalizations for heart failure and the cardiac deaths.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other University of Campania Luigi Vanvitelli trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03366181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing